Valeant acquires Pedinol Pharmacal

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has acquired Pedinol Pharmacal, Inc., a podiatry-focused, privately-owned specialty pharmaceutical company based in the U.S., for less than 1.5 times sales.  Revenue for 2011 was approximately $18 million and the transaction is expected to be immediately accretive.

"The Pedinol business will be a strong fit alongside Valeant's dermatology franchise," stated J. Michael Pearson, Valeant's chairman and chief executive officer.  "The podiatry market has similar characteristics to the dermatology market that we find attractive from a risk and reward aspect, and expanding into this area is a natural extension of our topical formulation development capabilities. Pedinol has over 85 years of experience in podiatry and a highly regarded national field sales organization, which are both key as we prepare for broader expansion into this market.  We expect Pedinol's established presence in the podiatry market to be a valuable asset for Valeant."

Source:

Valeant Pharmaceuticals International, Inc.

Comments

  1. PhilC PhilC United States says:

    The FDA's warning letter is posted on the internet about Pedinol's false and misleading advertising of one of their products often pushed by podiatrists. Valeant has some cleaning up to do, assuming they care.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Experts address questions on psoriasis patients’ true needs and wellbeing